Harvard Bioscience Appoints Yoav Sibony as VP Global Sales

Harvard Bioscience Appoints Yoav Sibony as VP Global Sales

More Than 15 Years Global Sales Experience to Help Company Increase Growth Worldwide

October 21, 2013 07:00 | Source: Harvard Bioscience, Inc.
HOLLISTON, Mass., Oct. 21, 2013 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, announced that it has hired Yoav Sibony, a veteran sales manager, as Harvard Bioscience's Vice President of Global Sales, a newly created position, effective October 21.

Jeffrey A. Duchemin, Chief Executive Officer of Harvard Bioscience, commented, "Expanding the Company's sales initiatives worldwide is crucial to our continuing growth. In order to take maximum advantage of the opportunities in our market, it is vital that we implement a far-reaching global sales strategy. To meet this challenge, we have created the new position of Vice President of Global Sales. Having worked with Yoav in the past, and knowing firsthand of his long and impressive track record of sales management experience, I am confident that he will help Harvard Bioscience attain the next level of growth. I look forward to collaborating with him as the Company expands its global footprint."

Prior to joining Harvard Bioscience, Mr. Sibony, age 42, served as Global Sales Effectiveness Manager at Corning Life Sciences, a division of Corning Inc. In this role, he oversaw global business operations and strategy development for this approximately $800 million division. Prior to this, from 2002 to 2012, he served in progressive positions at the medical technology company Becton, Dickinson & Company; as Regional Business Manager at BD Biosciences Discovery Labware, he oversaw 12 sales territories with combined value of $45 million. Mr. Sibony holds an M.B.A. from Pacific Lutheran University and earned a bachelor of business administration degree from Baruch College-City University of New York.

Yoav Sibony stated, "Harvard Bioscience's reputation as one of the pre-eminent life science research tools companies in the United States will serve as a major foothold as the Company seeks to expand its worldwide presence. I believe that with its range of products there is a considerable opportunity for growth as Harvard Bioscience expands its geographical reach. I look forward to serving as Vice President of Global Sales and working with Harvard Bioscience's management as the Company moves ahead."

About Harvard Bioscience

Harvard Bioscience ("HBIO") is a global developer, manufacturer and marketer of a broad range of specialized products, primarily apparatus and scientific instruments, used to advance life science research and regenerative medicine. Our products are sold to thousands of researchers in over 100 countries primarily through our 850 page catalog (and various other specialty catalogs), our website, through distributors, including GE Healthcare, Thermo Fisher Scientific and VWR, and via our field sales organization. HBIO has sales and manufacturing operations in the United States, the United Kingdom, Germany, Sweden and Spain with additional facilities in France and Canada. For more information, please visit our website at www.harvardbioscience.com.

The Harvard Bioscience, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6426

Forward-Looking Statements

Some of the statements in this press release are "forward-looking" and are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements include statements relating to, among other things, the appointment of Mr. Yoav Sibony as Harvard Bioscience's Vice President of Global Sales. These statements involve risks and uncertainties, including among other things, market conditions that may cause results to differ materially from the statements set forth in this press release. The forward-looking statements in this press release speak only as of the date of this press release. Harvard Bioscience expressly disclaims any obligation or undertaking to release publicly any updates or revisions to such statements to reflect any change in its expectations with regard thereto or any changes in the events, conditions or circumstances on which any such statement is based.

For investor inquiries, please call (508) 893-8066. Press releases may be found on our web site.

Jeffrey A. Duchemin
Chief Executive Officer
Tel: (508) 893-8999

Investor Relations:
Dian Griesel Int'l.
Cheryl Schneider
(212) 825-3210

Public Relations:
Dian Griesel Int'l.
Susan Forman or Laura Radocaj
(212) 825-3210

Suggested Articles

Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.

The planned deal hit a wall when a special committee set up by Eidos turned down BridgeBio’s third and final offer.

Shares in ReNeuron fell more than one-third after the release of top-line data at the start of the month but the biotech argued the data are positive.